Search:

REASURE

Phase II open label study of biomarkers to assess response in patients with metastatic castration-resistant prostate cancer treated with radium-223.

Disease site: Urological cancers Prostate cancer

Treatment Modality: Radiopharmaceutical, systemic therapy

Status: In follow-up

Trial details

REASURE is a phase II, multicentre, randomised trial of radium-223 incorporating diffusion-weighted MRI (DW-MRI) and PET imaging with collection of blood, urine and bone marrow samples. REASURE aims to identify potential markers of response to treatment with radium-223 in patients with castration-resistant prostate cancer with bone metastases.

38 patients will be recruited from four UK sites over 18 months. Patients will be randomised to receive a monthly radium-223 injection at a dose of either 50 kBq/kg or 80 kBq/kg for up to 6 months. Patients will be followed up every 4 months for 1 year after their last treatment of radium-223.

Further information for healthcare professionals

Further information for potential participants

Patient Information Sheet

Further information

Chief Investigator: Professor Chris Parker, The Royal Marsden NHS Foundation Trust

ICR-CTSU Scientific Lead: Professor Emma Hall

Trial management contact: [email protected]

ISRCTN: 17805587

Sponsor: The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust

Funding: Bayer HealthCare Pharmaceuticals Inc.

View REASURE on the National Institute for Health Research website: NIHR - Be Part Of Research

A plain English summary of the TNT trial is available from Cancer Research UK.

Publications and presentations

There have been no presentations or publications to date.

Image of the Institute of Cancer Research building in Sutton

ICR joins £10million AI project to help identify individual cancer risk

22/01/25

Doctors could soon be able to better predict an individual patient’s chances of getting cancer and offer them personalised detection and prevention strategies, thanks to a new research project co-led by scientists at The Institute of Cancer Research, London.

MR linac machine - cutting edge scanner

Innovative imaging study confirms feasibility of using smaller target areas in radiotherapy for early-stage glottic cancer

21/01/25

Scientists have successfully used real-time MRI to demonstrate that swallowing causes minimal motion of the larynx, known as the voice box, in people undergoing a radiotherapy session for cancer in this part of the body.